Drug Trial Radar · NCT06143891
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Jan 23, 2024
Primary completion
Sep 29, 2028
Study completion Sep 29, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the participants or the investigators, or until the end of study is reached, whichever comes first; at least 30 days follow-up of adverse events (AEs) after the last dose until resolution or stabilization, if applicable; and long-term follow-up until death or study close-out, whichever comes first.
Conditions
- Chronic Graft Versus Host Disease
Interventions
BelumosudilDrug
Pharmaceutical form:Tablet-Route of administration:oral
PlaceboDrug
Pharmaceutical form:Table-Route of administration:oral
PrednisoneDrug
Pharmaceutical form:Tablet-Route of administration:oral
PrednisoloneDrug
Pharmaceutical form:Tablet-Route of administration:oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-Free Survival (EFS)Time frame: Until the end of the study (up to 2.5 years since first patient in).
Locations
151 sites in 24 countries. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences-Site Number : 8400019
Little Rock, Arkansas
City of Hope National Medical Center- Site Number : 8400001
Duarte, California
University of California San Francisco - Parnassus Heights- Site Number : 8400035
San Francisco, California
AdventHealth Orlando- Site Number : 8400023
Orlando, Florida
The Hope Clinic of Emory University- Site Number : 8400020
Decatur, Georgia
Northwestern University- Site Number : 8400017
Chicago, Illinois
Indiana University Health University Hospital- Site Number : 8400006
Indianapolis, Indiana
University of Kentucky Chandler Medical Center- Site Number : 8400024
Lexington, Kentucky
Johns Hopkins Hospital- Site Number : 8400033
Baltimore, Maryland
Dana Farber Cancer Institute Site Number : 8400005
Boston, Massachusetts
Karmanos Cancer Institute - Detroit- Site Number : 8400013
Detroit, Michigan
UNC Children's Hospital- Site Number : 8400025
Chapel Hill, North Carolina
Atrium Health Wake Forest Baptist Medical Center - Winston-Salem - Medical Center Boulevard- Site Number : 8400007
Winston-Salem, North Carolina
Oncology Hematology Care - Kenwood- Site Number : 8400030
Cincinnati, Ohio
The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute- Site Number : 8400026
Columbus, Ohio
Oregon Health and Science University- Site Number : 8400027
Portland, Oregon
UPMC Hillman Cancer Center- Site Number : 8400008
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute Site Number : 8400003
Nashville, Tennessee
St. David's South Austin Medical Center- Site Number : 8400002
Austin, Texas
Texas Oncology - Dallas - Worth Street- Site Number : 8400010
Dallas, Texas
Texas Transplant Institute - Methodist Hospital- Site Number : 8400037
San Antonio, Texas
University of Virginia Comprehensive Cancer Center-Site Number : 8400031
Charlottesville, Virginia
Fred Hutchinson Cancer Research Center- Site Number : 8400004
Seattle, Washington
University of Wisconsin Carbone Cancer Center-Site Number : 8400029
Madison, Wisconsin
Investigational Site Number : 0320005
Buenos Aires, Argentina
Investigational Site Number : 0320003
Buenos Aires, Argentina
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320002
Buenos Aires, Argentina
Investigational Site Number : 0320004
Córdoba, Argentina
Investigational Site Number : 0320006
Pilar, Buenos Aires, Argentina
Investigational Site Number : 0360005
Westmead, New South Wales, Australia
Investigational Site Number : 0360003
Brisbane, Queensland, Australia
Investigational Site Number : 0360001
Melbourne, Victoria, Australia
Investigational Site Number : 0360004
Murdoch, Western Australia, Australia
Investigational Site Number : 0400003
Graz, Austria
Investigational Site Number : 0400001
Linz, Austria
Investigational Site Number : 0400004
Vienna, Austria
Investigational Site Number : 0560006
Bruges, Belgium
UZ Gent-Investigational Site Number : 0560003
Ghent, Belgium
CHU de Liège-Investigational Site Number : 0560004
Liège, Belgium
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.